1-3 of 3
Angel G. Galvez, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts).

Chadi Nabhan, MD, FACP, Jacob David Bitran, MD, FACP, Walter Fried, MD, Angel G. Galvez, MD, PhD, Laura Magid, Kathy Tolzien, Wendy Dewey, Parameswaran Venugopal, MD
Journal: Blood
Blood (2009) 114 (22): 921.
https://doi.org/10.1182/blood.V114.22.921.921
Published: 2009
Journal Articles

Surveillance Study of Temporary IVC Filters placed in Patients with VTE and Contraindications for Full Dose Anticoagulant Therapy

Angel G. Galvez, MD, PhD, Benjamin Parsons, D.O., Daniel Resnick, M.D., Morawa Ewelina, M.D., Abhilasha Radharkrishnan, M.D., Matthew Jimenez, M.D., Richard Messersmith, M.D.
Journal: Blood
Blood (2008) 112 (11): 3034.
https://doi.org/10.1182/blood.V112.11.3034.3034
Published: 2008
Journal Articles

Clofarabine (CLO) Is Active in Patients (pts) with Refractory and/or Relapsed Non-Hodgkin’s Lymphoma (NHL): A Phase I/II Study.

Chadi Nabhan, MD, FACP, Walter Fried, MD, Angel G. Galvez, MD, PhD, Parameswaran Venugopal, MD, Phillip Gozun, Jacob D. Bitran, MD, FACP
Journal: Blood
Blood (2007) 110 (11): 4462.
https://doi.org/10.1182/blood.V110.11.4462.4462
Published: 2007